557.9K XNAS Volume
XNAS 18 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| David C. Hastings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 365,800 | 365,800 | - | - | Stock Option (Right to Buy) | |
| David C. Hastings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 90,100 | 249,824 (0%) | 0% | 0 | Common Shares | |
| Michael J. McElhaugh | Director, Interim President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 177,000 | 1,658,003 (2%) | 0% | 0 | Common Shares | |
| Michael J. McElhaugh | Director, Interim President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 718,800 | 718,800 | - | - | Stock Option (Right to Buy) | |
| Karen Sims | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 200,300 | 200,300 | - | - | Stock Option (Right to Buy) | |
| Karen Sims | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 49,300 | 155,494 (0%) | 0% | 0 | Common Shares | |
| David C. Hastings | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.28 per share. | 04 Feb 2025 | 22,183 | 159,724 (0%) | 0% | 3.3 | 72,827 | Common Shares |
| Michael J. McElhaugh | Director, Interim President & CEO | Sale of securities on an exchange or to another person at price $ 3.28 per share. | 04 Feb 2025 | 23,790 | 1,481,003 (2%) | 0% | 3.3 | 78,103 | Common Shares |
| Karen Sims | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 3.28 per share. | 04 Feb 2025 | 19,348 | 106,194 (0%) | 0% | 3.3 | 63,519 | Common Shares |
| Keith Manchester | Director | 14 Aug 2024 | 54,915 | 0 | - | - | Stock Option (Right to Buy) | ||
| Keith Manchester | Director | 14 Aug 2024 | 54,915 | 54,915 (0%) | 0% | 0.6 | 30,752 | Common Shares | |
| Keith Manchester | Director | 14 Aug 2024 | 8,846 | 46,069 (0%) | 0% | 3.7 | 32,637 | Common Shares | |
| Daniel D. Burgess | Director | 23 May 2024 | 67,000 | 67,000 | - | - | Stock Option (Right to Buy) | ||
| James R. Meyers | Director | 23 May 2024 | 67,000 | 67,000 | - | - | Stock Option (Right to Buy) | ||
| Keith Manchester | Director | 23 May 2024 | 67,000 | 67,000 | - | - | Stock Option (Right to Buy) | ||
| Richard C. Henriques | Director | 23 May 2024 | 67,000 | 67,000 | - | - | Stock Option (Right to Buy) | ||
| Frank M. Torti | Director | 23 May 2024 | 67,000 | 67,000 | - | - | Stock Option (Right to Buy) | ||
| Melissa V. Rewolinski | Director | 23 May 2024 | 67,000 | 67,000 | - | - | Stock Option (Right to Buy) | ||
| Hastings C. David | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.31 per share. | 01 Feb 2024 | 9,593 | 181,907 (0%) | 0% | 2.3 | 22,184 | Common Shares |
| C. Hastings David | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 450,000 | 450,000 | - | - | Stock Option (Right to Buy) | |
| Karen Sims | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 101,000 | 129,900 (0%) | 0% | 0 | Common Shares | |
| J. McElhaugh Michael | Director, Interim President & CEO | 01 Feb 2024 | 123,800 | 1,514,957 (2%) | 0% | 0 | Common Shares | ||
| Michael J. Sofia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 437,800 | 437,800 | - | - | Stock Option (Right to Buy) | |
| Karen Sims | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 403,900 | 403,900 | - | - | Stock Option (Right to Buy) | |
| Sofia Michael J. | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 109,500 | 1,495,103 (2%) | 0% | 0 | Common Shares | |
| Sims Karen | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 2.31 per share. | 01 Feb 2024 | 4,358 | 125,542 (0%) | 0% | 2.3 | 10,078 | Common Shares |
| J. McElhaugh Michael | Director, Interim President & CEO | 01 Feb 2024 | 10,164 | 1,504,793 (2%) | 0% | 2.3 | 23,504 | Common Shares | |
| Hastings C. David | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 112,500 | 191,500 (0%) | 0% | 0 | Common Shares | |
| J. McElhaugh Michael | Director, Interim President & CEO | 01 Feb 2024 | 495,100 | 495,100 | - | - | Stock Option (Right to Buy) | ||
| J. Sofia Michael | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 2.31 per share. | 01 Feb 2024 | 9,982 | 1,485,121 (2%) | 0% | 2.3 | 23,083 | Common Shares |
| Melissa V. Rewolinski | Director | 12 Jul 2023 | 110,000 | 110,000 | - | - | Stock Option (Right to Buy) | ||
| Karen Sims | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2023 | 153,640 | 153,640 | - | - | Stock Option (Right to Buy) | |
| Daniel D. Burgess | Director | 24 May 2023 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | ||
| James R. Meyers | Director | 24 May 2023 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | ||
| Keith Manchester | Director | 24 May 2023 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | ||
| Richard C. Henriques | Director | 24 May 2023 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | ||
| Frank M. Torti | Director | 24 May 2023 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | ||
| David C. Hastings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 79,000 | 79,000 (0%) | 0% | 0 | Common Shares | |
| David C. Hastings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 316,000 | 316,000 | - | - | Stock Option (Right to Buy) | |
| Michael J. Sofia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 82,200 | 1,385,603 (2%) | 0% | 0 | Common Shares | |
| Michael J. Sofia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 328,700 | 328,700 | - | - | Stock Option (Right to Buy) | |
| Elizabeth Howard | EVP, GC, Compliance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 69,700 | 86,024 (0%) | 0% | 0 | Common Shares | |
| Elizabeth Howard | EVP, GC, Compliance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 278,700 | 278,700 | - | - | Stock Option (Right to Buy) | |
| Michael J. McElhaugh | Chief Business Officer | 01 Feb 2023 | 334,700 | 334,700 | - | - | Stock Option (Right to Buy) | ||
| Michael J. McElhaugh | Chief Business Officer | 01 Feb 2023 | 83,700 | 1,391,157 (2%) | 0% | 0 | Common Shares | ||
| William H. Collier | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 866,000 | 866,000 | - | - | Stock Option (Right to Buy) | |
| William H. Collier | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 216,500 | 216,500 (0%) | 0% | 0 | Common Shares | |
| Daniel D. Burgess | Director | 25 May 2022 | 41,000 | 41,000 | - | - | Stock Option (Right to Buy) | ||
| James R. Meyers | Director | 25 May 2022 | 41,000 | 41,000 | - | - | Stock Option (Right to Buy) | ||
| Keith Manchester | Director | 25 May 2022 | 41,000 | 41,000 | - | - | Stock Option (Right to Buy) | ||
| Richard C. Henriques | Director | 25 May 2022 | 41,000 | 41,000 | - | - | Stock Option (Right to Buy) | ||
| Frank M. Torti | Director | 25 May 2022 | 41,000 | 41,000 | - | - | Stock Option (Right to Buy) | ||
| Tram Tran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 41,000 | 41,000 | - | - | Stock Option (Right to Buy) | |
| David C. Hastings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2022 | 285,000 | 285,000 | - | - | Stock Option (Right to Buy) | |
| Michael J. Sofia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2022 | 285,000 | 285,000 | - | - | Stock Option (Right to Buy) | |
| Elizabeth Howard | Chief Compliance Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2022 | 237,500 | 237,500 | - | - | Stock Option (Right to Buy) | |
| Gaston Picchio | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2022 | 256,500 | 256,500 | - | - | Stock Option (Right to Buy) | |
| Michael J. McElhaugh | Chief Business Officer | 20 Jan 2022 | 325,850 | 325,850 | - | - | Stock Option (Right to Buy) | ||
| William H. Collier | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2022 | 787,550 | 787,550 | - | - | Stock Option (Right to Buy) | |
| Tram Tran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Nov 2021 | 44,000 | 44,000 | - | - | Stock Option (Right to Buy) | |
| Daniel D. Burgess | Director | 03 Jun 2021 | 22,000 | 22,000 | - | - | Stock Options | ||
| James R. Meyers | Director | 03 Jun 2021 | 22,000 | 22,000 | - | - | Stock Options | ||
| Keith Manchester | Director | 03 Jun 2021 | 22,000 | 22,000 | - | - | Stock Options | ||
| Richard C. Henriques | Director | 03 Jun 2021 | 22,000 | 22,000 | - | - | Stock Options | ||
| Frank M. Torti | Director | 03 Jun 2021 | 22,000 | 22,000 | - | - | Stock Options | ||
| Andrew Cheng | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2021 | 22,000 | 22,000 | - | - | Stock Options | |
| David C. Hastings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2021 | 250,000 | 250,000 | - | - | Stock Options | |
| Michael J. Sofia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2021 | 290,000 | 290,000 | - | - | Stock Options | |
| Elizabeth Howard | Chief Compliance Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2021 | 200,000 | 200,000 | - | - | Stock Options | |
| Gaston Picchio | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2021 | 250,000 | 250,000 | - | - | Stock Options | |
| Michael J. McElhaugh | Chief Business Officer | 13 Feb 2021 | 249,000 | 249,000 | - | - | Stock Options | ||
| William H. Collier | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2021 | 675,000 | 675,000 | - | - | Stock Options | |
| Michael J. McElhaugh | Chief Business Officer | 09 Feb 2021 | 20,000 | 1,307,457 (1%) | 0% | 5 | 100,000 | Common Stock | |
| Michael J. McElhaugh | Chief Business Officer | 14 Dec 2020 | 10,000 | 1,327,457 (1%) | 0% | 5.0 | 50,032 | Common Stock | |
| Michael J. McElhaugh | Chief Business Officer | 14 Dec 2020 | 30,000 | 1,337,457 (1%) | 0% | 5 | 150,000 | Common Stock | |
| Gaston Picchio | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Sep 2020 | 50,000 | 50,000 | - | - | Common Stock | |
| William H. Collier | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Sep 2020 | 70,000 | 70,000 | - | - | Stock Options | |
| Michael J. McElhaugh | Chief Business Officer | 23 Jul 2020 | 20,000 | 1,367,457 (1%) | 0% | 5.0 | 100,200 | Common Stock | |
| Daniel D. Burgess | Director | 28 May 2020 | 22,000 | 22,000 | - | - | Stock Options | ||
| James R. Meyers | Director | 28 May 2020 | 22,000 | 22,000 | - | - | Stock Options | ||
| Keith Manchester | Director | 28 May 2020 | 22,000 | 22,000 | - | - | Stock Options | ||
| Richard C. Henriques | Director | 28 May 2020 | 22,000 | 22,000 | - | - | Stock Options | ||
| Frank M. Torti | Director | 28 May 2020 | 22,000 | 22,000 | - | - | Stock Options | ||
| Andrew Cheng | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 22,000 | 22,000 | - | - | Stock Options | |
| William H. Collier | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 262,313 | 262,313 | - | - | Stock Options | |
| David C. Hastings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2020 | 100,000 | 100,000 | - | - | Stock Options | |
| Michael J. Sofia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2020 | 250,000 | 250,000 | - | - | Stock Options | |
| Elizabeth Howard | Chief Compliance Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2020 | 79,500 | 79,500 | - | - | Stock Options | |
| Gaston Picchio | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2020 | 150,000 | 150,000 | - | - | Stock Options | |
| Michael J. McElhaugh | Chief Business Officer | 17 Feb 2020 | 200,000 | 200,000 | - | - | Stock Options | ||
| William H. Collier | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2020 | 367,087 | 367,087 | - | - | Stock Options | |
| Daniel D. Burgess | None | 17 Aug 2019 | 22,000 | 22,000 | - | - | Stock Options | ||
| James R. Meyers | None | 17 Aug 2019 | 22,000 | 22,000 | - | - | Stock Options | ||
| Myrtle S. Potter | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2019 | 22,000 | 22,000 | - | - | Stock Options | |
| Keith Manchester | None | 17 Aug 2019 | 22,000 | 22,000 | - | - | Stock Options | ||
| Richard C. Henriques | None | 17 Aug 2019 | 22,000 | 22,000 | - | - | Stock Options | ||
| Frank M. Torti | None | 17 Aug 2019 | 22,000 | 22,000 | - | - | Stock Options | ||
| Andrew Cheng | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2019 | 60,000 | 60,000 | - | - | Stock Options | |
| William H. Collier | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2019 | 1,112,000 | 1,112,000 | - | - | Employee Stock Option (Right to Buy) | |
| David C. Hastings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2019 | 137,500 | 137,500 | - | - | Employee Stock Option (Right to Buy) | |
| Michael J. Sofia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2019 | 145,000 | 145,000 | - | - | Employee Stock Option (Right to Buy) | |
| Mark Murray | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2019 | 357,500 | 357,500 | - | - | Employee Stock Option (Right to Buy) | |
| Elizabeth Howard | Executive VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2019 | 137,500 | 137,500 | - | - | Employee Stock Option (Right to Buy) | |
| Gaston Picchio | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2019 | 137,500 | 137,500 | - | - | Employee Stock Option (Right to Buy) | |
| Michael J. McElhaugh | Chief Business Officer | 01 Mar 2019 | 104,500 | 104,500 | - | - | Employee Stock Option (Right to Buy) | ||
| Koert VandenEnden | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2018 | 7,500 | 7,500 | - | - | Employee Stock Option (Right to Buy) | |
| Mark Murray | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.35 per share. | 28 Nov 2018 | 25,000 | 341,396 (0%) | 0% | 1.4 | 33,750 | Common Shares |
| Mark Murray | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Nov 2018 | 25,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Frank M. Torti | None | 26 Nov 2018 | 44,000 | 44,000 | - | - | Director Share Option (right to buy) | ||
| James R. Meyers | None | 18 Oct 2018 | 44,000 | 44,000 | - | - | Director Share Option (Right to Buy) | ||
| Myrtle S. Potter | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Oct 2018 | 44,000 | 44,000 | - | - | Director Share Option (Right to Buy) | |
| Gaston Picchio | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Oct 2018 | 200,000 | 200,000 | - | - | Employee Share Option (Right to Buy) | |
| Michael J. Sofia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 9.51 per share. | 13 Aug 2018 | 4,250 | 167,162 (0%) | 0% | 9.5 | 40,436 | Common Shares |
| Michael J. Sofia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 10.00 per share. | 11 Jul 2018 | 10,000 | 1,503,403 (2%) | 0% | 10 | 100,000 | Common Shares |
| Michael J. Sofia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 8.91 per share. | 06 Jul 2018 | 10,000 | 1,513,403 (2%) | 0% | 8.9 | 89,060 | Common Shares |
| Michael J. Sofia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 8.45 per share. | 06 Jul 2018 | 10,000 | 1,523,403 (2%) | 0% | 8.5 | 84,500 | Common Shares |
| Michael J. Sofia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 8.00 per share. | 03 Jul 2018 | 10,000 | 1,543,403 (2%) | 0% | 8 | 80,000 | Common Shares |
| Michael J. Sofia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 8.40 per share. | 03 Jul 2018 | 10,000 | 1,533,403 (2%) | 0% | 8.4 | 84,000 | Common Shares |
| Daniel D. Burgess | None | 19 Jun 2018 | 22,000 | 22,000 | - | - | Director Stock Option (Right to Buy) | ||
| David C. Hastings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2018 | 200,000 | 200,000 | - | - | Employee Stock Option (Right to Buy) | |
| Herbert J. Conrad | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2018 | 22,000 | 22,000 | - | - | Director Stock Option (Right to Buy) | |
| Keith Manchester | None | 19 Jun 2018 | 22,000 | 22,000 | - | - | Director Stock Option (Right to Buy) | ||
| Richard C. Henriques | None | 19 Jun 2018 | 22,000 | 22,000 | - | - | Director Stock Option (Right to Buy) | ||
| Vivek Ramaswamy | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2018 | 22,000 | 22,000 | - | - | Director Stock Option (Right to Buy) | |
| Michael J. Sofia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2018 | 160,000 | 160,000 | - | - | Employee Stock Option (Right to Buy) | |
| William T. Symonds | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2018 | 30,000 | 30,000 | - | - | Employee Stock Option (Right to Buy) | |
| Mark Murray | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2018 | 418,187 | 418,187 | - | - | Employee Stock Option (Right to Buy) | |
| Mark Murray | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.35 per share. | 16 Apr 2018 | 27,007 | 316,396 (0%) | 0% | 0.4 | 9,560 | Common Shares |
| Mark Murray | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2018 | 27,007 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Elizabeth Howard | Exec. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2018 | 150,000 | 150,000 | - | - | Employee Stock Option (Right to Buy) | |
| Koert VandenEnden | Interim CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2018 | 25,000 | 25,000 | - | - | Employee Stock Option (Right to Buy) | |
| Patrick C. Machado | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 12 Jan 2018 | 664,000 | 1,164,000 | - | - | Series A Participating Convertible Preferred Shares | |
| Patrick C. Machado | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 16 Oct 2017 | 500,000 | 500,000 | - | - | Series A Participating Convertible Preferred Shares | |
| Michael J. Sofia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 8.00 per share. | 03 Oct 2017 | 10,000 | 1,553,403 (2%) | 0% | 8 | 80,000 | Common Shares |
| Michael J. Sofia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 3.68 per share. | 15 Aug 2017 | 20,000 | 171,412 (0%) | 0% | 3.7 | 73,500 | Common Shares |
| Michael J. Sofia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 3.75 per share. | 15 Aug 2017 | 10,000 | 191,412 (0%) | 0% | 3.8 | 37,500 | Common Shares |
| Daniel D. Burgess | None | 21 Jun 2017 | 22,000 | 22,000 | - | - | Director Stock Option Grant (Right to Buy) | ||
| Frank L. Karbe | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2017 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Herbert J. Conrad | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2017 | 22,000 | 22,000 | - | - | Director Stock Option Grant (Right to Buy) | |
| Keith Manchester | None | 21 Jun 2017 | 22,000 | 22,000 | - | - | Stock Option (right to buy) | ||
| Richard C. Henriques | None | 21 Jun 2017 | 22,000 | 22,000 | - | - | Director Stock Option Grant (Right to Buy) | ||
| Vivek Ramaswamy | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2017 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Daniel D. Burgess | None | 24 Mar 2017 | 50,000 | 50,000 | - | - | Director Stock Option (Right to Buy) | ||
| Michael J. Sofia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2017 | 150,000 | 150,000 | - | - | Employee Stock Option (Right to Buy) | |
| William T. Symonds | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2017 | 50,000 | 50,000 | - | - | Employee Stock Option (Right to Buy) | |
| Bruce G. Cousins | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2017 | 200,000 | 200,000 | - | - | Employee Stock Option (Right to Buy) | |
| Mark Murray | President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2017 | 450,000 | 450,000 | - | - | Employee Stock Option (Right to Buy) | |
| Peter Lutwyche | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2017 | 125,000 | 125,000 | - | - | Employee Stock Option (Right to Buy) | |
| Elizabeth Howard | Exec. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2017 | 125,000 | 125,000 | - | - | Employee Stock Option (Right to Buy) | |
| Michael Jeffrey Abrams | Managing Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2016 | 14,178 | 42,097 | - | - | Common Shares | |
| Michael Jeffrey Abrams | Managing Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2016 | 13,503 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Michael Jeffrey Abrams | Managing Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2016 | 675 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Mark Murray | Director, President & CEO | 16 Jun 2016 | 5,000 | 0 | - | - | Warrants | ||
| Mark Murray | Director, President & CEO | 16 Jun 2016 | 5,000 | 289,389 | - | - | Common Shares | ||
| Frank L. Karbe | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2016 | 7,500 | 7,500 | - | - | Director Stock Option (Right to Buy) | |
| Herbert J. Conrad | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2016 | 7,500 | 7,500 | - | - | Director Stock Option (Right to Buy) | |
| Keith Manchester | None | 03 Jun 2016 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | ||
| Richard C. Henriques | None | 03 Jun 2016 | 7,500 | 7,500 | - | - | Director Stock Option (Right to Buy) | ||
| Vivek Ramaswamy | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2016 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Michael J. Sofia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2016 | 100,000 | 100,000 | - | - | Employee Stock Option (Right to Buy) | |
| William T. Symonds | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2016 | 25,000 | 25,000 | - | - | Executive Stock Option (Right to Buy) | |
| Michael Jeffrey Abrams | Managing Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2016 | 50,000 | 50,000 | - | - | Employee Stock Option (Right to Buy) | |
| Bruce G. Cousins | Exec VP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2016 | 145,000 | 145,000 | - | - | Employee Stock Option (Right to Buy) | |
| Mark Murray | President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2016 | 450,000 | 450,000 | - | - | Employee Stock Option (Right to Buy) | |
| Peter Lutwyche | Chief Tech. Operations Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2016 | 60,000 | 60,000 | - | - | Employee Stock Option (Right to Buy) | |
| Mark Kowalski | Sr VP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2016 | 85,000 | 85,000 | - | - | Employee Stock Option (Right to Buy) | |
| Elizabeth Howard | Exec. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2016 | 120,000 | 120,000 | - | - | Employee Stock Option (Right to Buy) | |
| Michael Jeffrey Abrams | Managing Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Sep 2015 | 17,044 | 27,919 | - | - | Common Shares | |
| Michael Jeffrey Abrams | Managing Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Sep 2015 | 17,044 | 0 | - | - | Employee Stock Option (right to buy) | |
| Mark Murray | President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Sep 2015 | 219,428 | 0 | - | - | Employee Stock Option (right to buy) | |
| Mark Murray | President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Sep 2015 | 219,428 | 284,389 | - | - | Common Shares | |
| Richard C. Henriques | None | 24 Aug 2015 | 1,000 | 1,000 | - | - | Common Shares | ||
| Frank L. Karbe | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2015 | 7,500 | 7,500 | - | - | Stock Option (Right to Buy) | |
| Herbert J. Conrad | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2015 | 7,500 | 7,500 | - | - | Stock Option (Right to Buy) | |
| Keith Manchester | None | 12 Aug 2015 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | ||
| Richard C. Henriques | None | 12 Aug 2015 | 7,500 | 7,500 | - | - | Stock Option (Right to Buy) | ||
| Vivek Ramaswamy | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2015 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Michael Jeffrey Abrams | Managing Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jul 2015 | 35,000 | 35,000 | - | - | Employee Stock Option (right to buy) | |
| Bruce G. Cousins | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jul 2015 | 75,000 | 75,000 | - | - | Employee Stock Option (right to buy) | |
| Mark Murray | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jul 2015 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| Herbert J. Conrad | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2015 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Richard C. Henriques | None | 30 Mar 2015 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | ||
| Michael Jeffrey Abrams | Exec. VP & Chief Discovery Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2015 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Bruce G. Cousins | Exec VP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2015 | 80,000 | 80,000 | - | - | Stock Option (right to buy) | |
| Mark Murray | President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2015 | 180,000 | 180,000 | - | - | Stock Option (right to buy) |